Some of this publication data contain data that is not fully aligned with the approved indication in Israel.
Please refer to the full prescribing information as approved by the Israeli MOH.
The approved indication for ITP in Israel is:
Revolade is indicated for the treatment of patients aged 6 years and above with primary immune
thrombocytopenia (ITP) lasting 6 months or longer from diagnosis and who are refractory to other
treatments (e.g. corticosteroids, immunoglobulins).